

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:)
) Chapter 11
NVN Liquidation, Inc., *et al.*,)
f/k/a NOVAN, INC.,¹) Case No. 23-10937 (LSS)
)
Debtors.) Jointly Administered
)

**NOTICE OF AGENDA FOR RESCHEDULED² HEARING NOW
SCHEDULED FOR FEBRUARY 20, 2024, AT 3:30 P.M. (ET)**

This hearing will be conducted in-person, any exceptions must be approved by chambers.

To attend a hearing remotely, please register using the eCourtAppearance tool ([available here](#)) or on the court’s website at www.deb.uscourts.gov.

The deadline to register for remote attendance is 4 PM (prevailing Eastern Time) the business day before the hearing unless otherwise noticed.

After the deadline has passed an electronic invitation, with the relevant audio or video link, will be emailed to you prior to the hearing.

Topic: NVN Liquidation, Inc., et al.
Time: February 20, 2024, at 3:30 p.m. (Eastern Time)

ADJOURNED MATTER

1. Motion of Debtors for Entry of an Order Pursuant to 11 U.S.C. §§ 105(a) and 554 and Federal Rule of Bankruptcy Procedure 6007 Authorizing the Abandonment of Certain Unsellable Products Subject to Certain Regulatory Obligations ([D.I. 533](#), filed 1/19/24).

¹ The Debtors in these chapter 11 cases, along with the last four digitals of the Debtors’ federal tax identification number (if applicable), are: NVN Liquidation, Inc., (f/k/a Novan, Inc.) (7682) and EPI Health, LLC (9118). The corporate headquarters and the mailing address for the Debtors is P.O. Box 64, Pittsboro, NC 27312.

² The hearing previously scheduled for February 9, 2024, at 11:30 a.m. (ET) has been rescheduled to February 20, 2024, at 3:30 p.m. (ET) at the request of the Debtors.



Response Deadline: February 2, 2024, at 4:00 p.m. (ET); extended to February 13, 2024, at 4:00 p.m. (ET) for Integrated Commercialization Solutions, Inc. (“ICS”) and for the United States Food and Drug Administration (the “FDA”).

Responses Received:

- a) Informal response received from ICS
- b) Informal objection received from the FDA

Related Documents: None at this time.

Status: The Debtors have agreed to resolve the informal response from ICS with additional clarifying language that will be included in a proposed form of order. The Debtors are continuing to discuss the issues raised by the FDA with the FDA and other parties in interest. This matter will be going forward at the hearing rescheduled for February 20, 2024, at 3:30 p.m.

MATTER UNDER CERTIFICATION

- 2. Motion of Debtors for Entry of an Order Approving the Stipulation with MC2 Therapeutics Limited ([D.I. 536](#), filed 1/19/24).

Response Deadline: February 2, 2024, at 4:00 p.m. (ET)

Responses Received: None.

Related Documents:

- a) Certificate of No Objection Regarding Motion of Debtors for Entry of an Order Approving the Stipulation with MC2 Therapeutics Limited ([D.I. 584](#), filed 2/7/24).

Status: On February 7, 2024, the Debtors submitted a certificate of no objection with respect to this matter. Accordingly, a hearing on this matter is only necessary if the Court has questions.

(Remainder of page intentionally left blank)

Dated: February 7, 2024
Wilmington, Delaware

Respectfully submitted,

/s/ Daniel B. Butz

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

Derek C. Abbott (No. 3376)

Daniel B. Butz (No. 4227)

Tamara K. Mann (No. 5643)

Scott D. Jones (No. 6672)

1201 Market Street, 16th Floor

Wilmington, Delaware 19801

Telephone: (302) 658-9200

Facsimile: (302) 658-3989

Email: dabbott@morrisnichols.com

dbutz@morrisnichols.com

tmann@morrisnichols.com

sjones@morrisnichols.com

Counsel to the Debtors and Debtors in Possession